AMP SCZ® Observational Study: PREDICT-DPACC
Launched by BRIGHAM AND WOMEN'S HOSPITAL · Jun 6, 2023
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
The AMP SCZ Observational Study, known as PREDICT-DPACC, is focused on understanding young people who are at a higher risk of developing serious mental health issues, particularly psychosis. The goal of this study is to create tools that can help predict whether these individuals will improve, experience a psychotic episode, or have ongoing symptoms that affect their daily lives. By gathering information from a large group of participants aged 12 to 30, the researchers aim to identify patterns that may help in providing better treatments for those at risk.
To participate, individuals must be between 12 and 30 years old and meet specific criteria indicating they are at clinical high risk for psychosis. Participants will undergo various assessments over 18 to 24 months, allowing researchers to track their symptoms and overall well-being. Importantly, those with a history of certain mental health conditions or who are currently taking specific medications may not be eligible. This study is currently recruiting participants from multiple countries, making it a significant international effort to improve understanding and treatment of high-risk mental health conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals between 12 and 30 years old;
- • Understand and sign an informed consent (or assent for minors) document;
- • Meet diagnostic criteria for CHR from the Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS (PSYCHS).
- Exclusion Criteria:
- • Antipsychotic medication exposure equivalent to a total lifetime haloperidol dose of \>50 mg or current antipsychotic medication at time of screening assessment;
- • Documented history of intellectual disability;
- • Past or current clinically relevant central nervous system disorder;
- • Traumatic brain injury that is rated as 7 or above on the Traumatic Brain Injury screening instrument;
- • Current or past treated or untreated psychotic episode, as determined using the PSYCHS.
- • See also the AMP SCZ website link for a description of eligibility criteria (https://www.ampscz.org/participate/eligible/).
About Brigham And Women's Hospital
Brigham and Women's Hospital (BWH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As an integral part of the Partners HealthCare system, BWH combines cutting-edge medical education with a focus on patient-centered care, fostering an environment that promotes groundbreaking clinical trials across various specialties. The hospital is dedicated to translating scientific discoveries into effective treatments, making significant contributions to the fields of cardiovascular medicine, oncology, and women's health, among others. With a robust infrastructure for research and a collaborative approach, BWH aims to improve patient outcomes and enhance the overall quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Pavia, , Italy
Boston, Massachusetts, United States
San Diego, California, United States
New Haven, Connecticut, United States
Saint Louis, Missouri, United States
Chapel Hill, North Carolina, United States
Chapel Hill, North Carolina, United States
Irvine, California, United States
New York, New York, United States
Calgary, Alberta, Canada
Philadelphia, Pennsylvania, United States
Athens, Georgia, United States
San Francisco, California, United States
San Francisco, California, United States
Evanston, Illinois, United States
London, , United Kingdom
Hartford, Connecticut, United States
Eugene, Oregon, United States
Queens, New York, United States
Los Angeles, California, United States
Adelaide, South Australia, Australia
Craigieburn, Victoria, Australia
Glenroy, Victoria, Australia
Melton South, Victoria, Australia
Parkville, Victoria, Australia
Sunshine, Victoria, Australia
Werribee, Victoria, Australia
Montréal, Quebec, Canada
Santiago, Región Metropolitana, Chile
Shanghai, , China
Copenhagen, , Denmark
Cologne, Brescia, Germany
Jena, Thuringia, Germany
Munich, , Germany
Hong Kong, , Hong Kong
Gwangju, , Korea, Republic Of
Seoul, , Korea, Republic Of
Singapore, , Singapore
Madrid, , Spain
Lausanne, , Switzerland
Birmingham, , United Kingdom
Cambridge, , United Kingdom
Santiago, , Chile
Patients applied
Trial Officials
Martha E Shenton, Ph.D.
Principal Investigator
Brigham and Women's Hospital/Harvard Medical School
Scott Woods, M.D.
Principal Investigator
Yale University
Barnaby Nelson, Ph.D.
Principal Investigator
Center for Youth Mental Health at the University of Melbourne/Orygen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported